waypoint wealth counsel Makes New Investment in Medpace Holdings, Inc. $MEDP

waypoint wealth counsel bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 1,045 shares of the company’s stock, valued at approximately $537,000.

A number of other institutional investors have also modified their holdings of MEDP. Clarkston Capital Partners LLC purchased a new stake in Medpace during the second quarter worth about $40,569,000. Brighton Jones LLC increased its holdings in Medpace by 160.4% in the third quarter. Brighton Jones LLC now owns 4,060 shares of the company’s stock valued at $2,087,000 after buying an additional 2,501 shares in the last quarter. Arkadios Wealth Advisors acquired a new stake in shares of Medpace during the 2nd quarter valued at approximately $327,000. Nordea Investment Management AB lifted its position in shares of Medpace by 4.8% during the 2nd quarter. Nordea Investment Management AB now owns 61,125 shares of the company’s stock valued at $19,067,000 after acquiring an additional 2,792 shares during the period. Finally, Jump Financial LLC purchased a new stake in shares of Medpace during the 2nd quarter worth approximately $15,729,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

MEDP has been the subject of several research analyst reports. Robert W. Baird set a $613.00 price objective on Medpace in a research note on Friday, October 24th. Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, December 20th. Rothschild Redb downgraded Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 3rd. Mizuho boosted their price objective on shares of Medpace from $575.00 to $655.00 and gave the stock an “outperform” rating in a research report on Friday, October 24th. Finally, Truist Financial set a $555.00 target price on shares of Medpace in a report on Monday, October 27th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, ten have issued a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat, Medpace currently has an average rating of “Hold” and a consensus price target of $490.82.

Medpace Stock Up 0.4%

NASDAQ MEDP opened at $569.98 on Tuesday. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $626.26. The business has a fifty day moving average of $580.13 and a 200-day moving average of $484.52. The stock has a market cap of $16.06 billion, a price-to-earnings ratio of 39.86, a price-to-earnings-growth ratio of 2.14 and a beta of 1.43.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The business had revenue of $659.90 million for the quarter, compared to analyst estimates of $640.49 million. During the same quarter last year, the company earned $3.01 earnings per share. The business’s revenue for the quarter was up 23.7% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Insider Transactions at Medpace

In other news, CEO August J. Troendle sold 668 shares of Medpace stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $590.69, for a total transaction of $394,580.92. Following the completion of the sale, the chief executive officer directly owned 646,184 shares in the company, valued at $381,694,426.96. The trade was a 0.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Susan E. Burwig sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the transaction, the vice president directly owned 27,500 shares in the company, valued at $16,751,625. The trade was a 42.11% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 387,925 shares of company stock worth $233,386,647 over the last ninety days. 20.30% of the stock is currently owned by corporate insiders.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.